Status:
COMPLETED
To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden
Lead Sponsor:
AstraZeneca
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare PET measurements of fibrillar amyloid burden using \[18F\]AZD4694.
Eligibility Criteria
Inclusion
- Male or female, of any race or/ethnicity
- ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician
Exclusion
- Significant recent (within 6 months) history of neurological (including stroke) or psychiatric disorder or substance abuse
- Participated in a PET study within the last 12 months
- Pregnancy or lactation
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00991419
Start Date
February 1 2010
End Date
August 1 2011
Last Update
January 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Phoenix, Arizona, United States